Antibody response to SARS-CoV-2 among individuals with IBD diminishes over time: a serosurveillance cohort study

Authors:

Open Access

Publisher website

2 August 2021

journal article
letter
Published by BMJ in Gut

Vol. 71 (6) , 1229-1231
DOI:10.1136/gutjnl-2021-325238
PMID:34340997
PMCID:PMC9120372

Abstract

No abstract available

Keywords

Funding Information

Crohn's and Colitis Canada (Not applicable)
Canadian Institutes of Health Research (VR5-172684)

This publication has 6 references indexed in Scilit:

Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic
Microbiology Spectrum, 2021
Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab
Gut, 2021
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection
Science, 2021
Analytical and clinical performances of five immunoassays for the detection of SARS-CoV-2 antibodies in comparison with neutralization activity
EBioMedicine, 2020
Seroprevalence of SARS-CoV2 in IBD Patients Treated with Biologic Therapy
Journal of Crohn's and Colitis, 2020
SARS-CoV-2 Testing, Prevalence, and Predictors of COVID-19 in Patients with Inflammatory Bowel Disease in Northern California
Gastroenterology, 2020